A Healthy Investment
Prevatex is proud to be partnering with like-minded leaders in our fields of research – an efficient and targeted path to market.
For our human health program, we have secured a manufacturing and licensing agreement with Probiotics Australia.
For our animal health program, we are working with Ipromea to produce a specialised probiotic for dogs.
We remain a private Company with a tightly held share register – but as we grow, we always welcome discussions with interested investors. To learn more, subscribe to receive our latest news.
“The probiotics market globally is expected to reach over $100 Billion in 2025 and in Australia alone is already worth over $500 million.”